Related Experiment Videos
Delayed thrombocytopenia following abciximab therapy
Edo Kaluski1, Marina Leitman, Inna Khiger
1Assaf Harofeh Cardiology Institute and Coronary Care Unit, Zerifin, Israel.
Summary
Delayed profound thrombocytopenia can occur five days after abciximab therapy, a glycoprotein (GP) IIb/IIIa inhibitor. These cases were self-limited and reversible without serious bleeding complications.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Glycoprotein (GP) IIb/IIIa inhibitors are crucial in treating acute coronary syndromes and percutaneous coronary interventions (PCIs).
- Abciximab is an intravenous GP IIb/IIIa inhibitor used in approximately 35% of the >500,000 annual PCI patients in the USA.
- Profound thrombocytopenia is a rare but serious side effect, typically occurring within 24 hours of abciximab administration.
Purpose of the Study:
- To report three cases of delayed profound thrombocytopenia following abciximab therapy.
- To discuss the pathophysiology, diagnosis, natural history, and management of this specific adverse event.
Main Methods:
- Case series describing three patients who developed delayed profound thrombocytopenia.
- Review of clinical data and outcomes related to abciximab administration.
Main Results:
- Three patients experienced profound thrombocytopenia presenting five days after abciximab therapy.
- All cases were self-limited and reversible.
- No serious bleeding complications were observed in these patients.
Conclusions:
- Delayed profound thrombocytopenia is a possible, albeit rare, complication of abciximab therapy.
- Early recognition and monitoring are essential for managing abciximab-induced thrombocytopenia.
- The self-limited nature of these cases suggests a favorable prognosis with appropriate management.